Article Information
History
- May 18, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.
Author Information
- Todd G. Smitha,*,
- Crystal M. Gigantea,
- Nhien T. Wynna,
- Audrey Mathenya,
- Whitni Davidsona,
- Yong Yanga,
- Rene Edgar Condoria,
- Kyle O’Connellb,c,
- Lynsey Kovarb,d,
- Tracie L. Williamse,
- Yon C. Yuf,
- Brett W. Petersena,
- Nicolle Bairda,
- David Lowea,
- Yu Lia,
- Panayampalli S. Satheshkumara and
- Christina L. Hutsona
- aPoxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta GA, 30333, USA
- bOffice of Advanced Molecular Detection, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta GA, 30333, USA
- cHealth Data and AI, Deloitte Consulting LLC, 1919 N. Lynn St, Arlington VA 22209
- dLeidos Inc., Reston, VA 20190, USA
- eClinical Chemistry Branch, Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, 4770 Buford Highway, Atlanta GA, 30341, USA
- fEmergency Preparedness and Response Branch, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta GA, 30333, USA
- ↵*Corresponding Author Tel: 404-639-2282, Fax: 404-639-1564, Email: tgsmith1{at}cdc.gov
Posted May 18, 2023.
Resistance to anti-orthopoxviral drug tecovirimat (TPOXX®) during the 2022 mpox outbreak in the US
